ArticleFrontiers in public health2026
Adult RSV hospitalizations in Spain: clinical characteristics and risk factors for ICU admission, prolonged stay, and mortality across six seasons (2016-2017 to 2021-2022).
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the clinical characteristics of adults hospitalized with respiratory syncytial virus (RSV) in Spain over six epidemiological seasons (2016-2017 to 2021-2022) and identify factors associated with ICU admission, prolonged length of stay, and in-hospital mortality (IHM). Methods: Retrospective, population-based study in adults (≥15 years) hospitalized for RSV and included in the Spanish hospital discharge database (containing all records of hospitalizations in Spain). Factors linked to ICU admission, prolonged length of stay, and IHM were assessed using multivariable logistic regression. Results: A total of 20,695 adults (56.5% women) were hospitalized with RSV. Case numbers increased until 2018-2019, then declined during the COVID-19 pandemic. Patients aged 15-64 years accounted for 20.9% of the sample; 65-79 years, 31.2%; and ≥80 years, 47.9%. Common comorbidities included hypertension (61.3%), diabetes (28.0%), and heart failure (26.1%). ICU admission (6.4% of cases) was independently associated with age 15-64 years (adjusted odds ratio [aOR] 5.04, 95% confidence interval [CI] 4.21-6.03), COVID-19 co-infection (aOR 5.06, 95% CI 2.88-8.87), and RSV pneumonia (aOR 2.19, 95% CI 1.48-3.27). IHM increased with age (15-64 years: 4.0%; 65-79 years: 6.2%, aOR 1.67, 95% CI 1.37-2.04; and ≥80 years: 9.5%, aOR 3.32, 95% CI 2.73-4.04). Other key risk factors were ICU admission (aOR 6.23, 95% CI 5.30-7.33), leukemia (aOR 3.31, 95% CI 2.11-4.59), and neoplasm (aOR 2.90, 95% CI 2.43-3.47). Conclusions: RSV represents a significant and growing burden among hospitalized adults, particularly in older individuals and those with underlying comorbidities, who experience worse outcomes and higher mortality. These findings underscore the importance of prevention strategies, including vaccination of adults aged ≥60 years and high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.